High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
Listen to this summary
The authors aimed to evaluate the effectiveness of high-dose methotrexate (HD-MTX) as a prophylactic treatment to prevent central nervous system (CNS) relapse in patients with ultra high-risk large B-cell lymphoma (UHR LBCL). An analysis of 1,923 UHR patients revealed no significant difference in the 3-year CNS relapse rates between those treated with HD-MTX and those who were not. These findings suggest that HD-MTX prophylaxis does not provide a meaningful benefit in reducing CNS relapse in this patient population.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Journal of clinical oncology : official journal of the American Society of Clinical Oncology
View all →Jun 11, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)
Jun 4, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer
More in Pediatrics
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Critical care medicine
Ethical Implications of the Slow Code: A Systematic Review of Ethics of Slow Codes in U.S. Hospitals
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
